Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

Biocon Biologics and Viatris on Tuesday launched their interchangeable insulin biosimilar in the US market. The launch includes Semglee, which is a branded product, Insulin Glargine, which is an unbranded injection.

These injections will aid control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. The currently marketed non-interchangeable Semglee is anticipated to be phased out by the end of the 2021 calendar year.

Shreehas Tambe, deputy CEO of Biocon Biologics, said: “This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us